Mar 26, 2019
Alkahest to Present Data in Alzheimer's and Parkinson's Diseases at the AD/PD Conference
Mar 25, 2019
Alkahest Presents Positive Results from Phase 2a Open Label Study of AKST4290 in Treatment-Naïve neovascular AMD at Retina World Congress
Mar 18, 2019
Alkahest Doses First Subject in Phase 2 Clinical Trial of Lead Candidate in Patients with Severe Alzheimer's Disease
Dec 17, 2018
Alkahest Announces Positive Top-Line Data from Two Phase 2a Studies of AKST4290 in Individuals with Wet Age-Related Macular Degeneration
Dec 04, 2018
Alkahest Doses First Subject in Phase 2 Clinical Trial of GRF6021 in Patients with Parkinson's Disease and Cognitive Impairment
Nov 07, 2018
Alkahest Appoints Elizabeth Jeffords as Chief Commercial and Strategy Officer
Nov 05, 2018
Alkahest to Present at the Society for Neuroscience Annual Meeting
Nov 02, 2018
Alkahest Scientific Founder Tony Wyss-Coray Recognized as One of TIME Magazine's 50 Most Influential People in Health Care
Aug 01, 2018
Alkahest, Inc. Announces Key Appointment
Jul 23, 2018
Alkahest to Present at Alzheimer's Association International Conference (AAIC) Annual Meeting July 22-26, 2018 Chicago, IL
May 21, 2018
Alkahest Receives Grant from Michael J. Fox Foundation; Funding Will Support Preclinical Evaluation of ALK4290 for Parkinson's Disease
May 14, 2018
Alkahest Announces Initiation of Two Phase 2 Clinical Trials of ALK4290 in Age-Related Macular Degeneration
Apr 25, 2018
Alkahest Announces Initiation of Phase 2 Clinical Trial of GRF6019 in Alzheimer's Disease
Feb 12, 2018
Alkahest Receives Grant from Michael J. Fox Foundation; Funding Will Support the Clinical Development of a Novel Parkinson's Therapy
Jan 23, 2018
Alkahest, Inc. Announces Key Appointments
Nov 10, 2017
Alkahest to Present at Society for Neuroscience 47th Annual Meeting
Nov 01, 2017
Alkahest to Present Clinical Results from PLASMA Study in Patients with Mild to Moderate Alzheimer's Disease at the 10th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Aug 07, 2017
Alkahest Appoints Helen Jenkins as Chief Operating Officer